Renalytix Plc

As of December 31, 2024, Renalytix Plc carries a market capitalization of 36.96M, placing it among publicly traded companies globally. Its enterprise value stands at 35.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Renalytix Plc's next confirmed earnings release is scheduled for November 3, 2026.

As of December 31, 2024, Renalytix Plc has 331.21M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 8.39, and the price-to-book ratio stands at -27.96.

These figures are as of December 31, 2024. The EV/Sales ratio of 15.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 35.59M versus a market cap of 36.96M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2024, Renalytix Plc maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -140.64, reflecting losses generated across the asset base. The company generates approximately 42,616.57 in revenue per employee across its workforce of 53.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.10 indicates how many times Renalytix Plc sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Renalytix Plc's stock has declined approximately 29.47% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.04.

Over the twelve months ended December 31, 2024, Renalytix Plc generated 2.29M in revenue and converted that into -22.62M in net income, yielding earnings per share of -0.13. EBITDA reached -18.93M, while operating income came in at -18.49M.

As of December 31, 2024, Renalytix Plc holds 9.30M in cash and equivalents against 7.92M in total debt, resulting in a net debt position of -969,562.80. Total book value stands at -1.32M, with working capital of 6.36M providing operational flexibility.

Renalytix Plc produced -22.30M in operating cash flow over the twelve months ended December 31, 2024. After subtracting -965.70 in capital expenditures, free cash flow totaled -22.31M - equivalent to -0.13 per share.

Over the twelve months ended December 31, 2024, Renalytix Plc posted a gross margin of 19.73, reflecting its pricing power and cost economics. The operating margin of -807.29 and net profit margin of -987.65 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -116.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -70.39, meaning Renalytix Plc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2024, Renalytix Plc has an Altman Z-Score of -21.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.